Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 12Docetaxel 7durvalumab 5Gemcitabine 5Trastuzumab 4Radiotherapy 4Surveys and Questionnaires 3Magnetic Resonance Spectroscopy 3tremelimumab 2tisotumab vedotin 2pertuzumab 2motexafin gadolinium 2cemiplimab 2X-Rays 2TH 302 2Ritonavir 2Pemetrexed 2Nivolumab 2Ipilimumab 2Interviews as Topic 2Injections 2Immunoglobulin G 2Cryosurgery 2Cisplatin 2Bortezomib 2Biopsy 2Bariatric Surgery 2zenocutuzumab 1yeast-CEA vaccine 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × sitravatinib × Head & Neck × Clear all
NCT02219711 2023-03-06

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

Mirati Therapeutics Inc.

Phase 1 Completed
193 enrolled
GenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡